<DOC>
	<DOCNO>NCT01700140</DOCNO>
	<brief_summary>The purpose study explore dose response SyB D-0701 prevent nausea emesis associate radiotherapy ( fractionated/localized irradiation ) cancer patient schedule receive radiotherapy ( fractionated/localized irradiation ) alone .</brief_summary>
	<brief_title>Phase II Study SyB D-0701 Radiotherapy-Induced Nausea Vomiting ( RINV )</brief_title>
	<detailed_description>Exploratory study dose response SyB D-0701 prevent effect nausea emesis associate radiotherapy ( fractionated/localized irradiation )</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>Inclusion Criteria Patients must satisfy follow condition list . 1 . Patients histologically verify malignant tumor 2 . Patients receive radiotherapy alone schedule least 3 fraction , radiation dose 1.5 3.0 Gy 3 . Cancer patient schedule radiotherapy field least 100 cm2 ( 50 cm2 case irradiation vertebra ) include abdomen pelvis ( region upper edge 11th thoracic vertebra lower edge pelvic cavity ) 4 . Patients schedule receive antitumor agent first fifth day radiotherapy . If patient history antitumor agent therapy , however , time patient 's registration , least 5 day must elapse since drug administration terminate , patient must schedule receive antitumor agent first fifth day radiotherapy 5 . Male patient surgically sterilize , agree practice adequate contraception study 6 . Female patient childbearing potential agree practice adequate contraception study 7 . Patients whose performance status ( PS ) Eastern Cooperative Oncology Group ( ECOG ) 0 2 8 . Patients least 20 year age consent obtain 9 . Patients give consent write participate study full understanding explanatory document Exclusion Criteria Patients satisfy follow condition enrol study . 1 . Patients nausea and/or emesis ; patient also intestinal obstruction , vestibular dysfunction ( e.g. , epilepsy ) , Meniere 's syndrome , cerebral metastasis , electrolyte imbalance ( hypercalcemia , hyperglycemia , hyponatremia ) , uremia , etc. , patient judge high probability nausea emesis arises aforementioned cause . Registration possible , however , patient motion sickness ( vehicle sickness ) patient temporary nausea/emesis arise routine activity . 2 . Patients primary metastasize brain tumor show sign elevate intracranial pressure 3 . Patients previously receive radiotherapy brain region include abdomen pelvis ( region upper edge 11th thoracic vertebra lower edge pelvic cavity ) 4 . Patients take drug affect evaluation nausea emesis ( rescue medication 5hydroxytryptamine 3 ( 5HT3 ) receptor antagonist , neurokinin 1 ( NK1 ) receptor antagonist , anxiolytic , psychotropic drug , opioid analgesic corticosteroid [ systemic administration ] except rescue medication ) 5 . Patients abnormal finding ( e.g. , erythema , rash , wound ) sit study drug apply 6 . Patients history hypersensitivity study drug ingredient 5HT3 receptor antagonist 7 . Patients history allergy involve dermal symptom 8 . Patients clear sign infection ( include viral infection ) 9 . Patients complication drug alcohol dependence , history 10 . Patients participate type clinical study ( include physicianinitiated clinical study clinical research ) within 3 month prior registration present study give study drug ( include drug yet approve ) . Patients register study , however , participate clinical study , etc. , drug already approve use . 11 . Patients serious hepatic renal damage [ Grade 3 Common Terminology Criteria Adverse Events ( CTCAE ) ( ver . 4.0JCOG ) ] 12 . Patients cardiac dysfunction 13 . Patients pregnant , might pregnant currently lactate 14 . Other patient judge unsuitable investigator subinvestigators</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>